EDITORIAL
End points in clinical trials: are they moving the goalposts?
Cardiology Department and South West Sydney Clinical School (UNSW), Liverpool Hospital, Elizabeth Street, Liverpool, NSW 2170, Australia
Correspondence to:
Correspondence to:
Professor John K French
Department of Cardiology, Liverpool Hospital, Elizabeth Street, Liverpool, NSW 2170, Australia; j.french{at}unsw.edu.au
In selecting and defining composite end points in clinical trials, are we trading off clinical significance for statistical significance?
Abbreviations: CABG, coronary artery bypass graft surgery; CK, creatine kinase; MI, myocardial infarction; PCI, percutaneous coronary intervention
Keywords: clinical trials; coronary heart disease; end points
Read all eLetters
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
eLetters:
- Full Text
- Full Text (PDF)
- Submit a response
- Read responses to this article
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
